What is “Recarbrio” and what would a generic be?
Recarbrio is an antibiotic combination product containing imipenem, cilastatin, and relebactam. A “Recarbrio generic” would mean a drug approved to work as the same combination for the same indications—typically through an FDA approval pathway for generics or an equivalent approval pathway for complex drug products, depending on the product’s formulation and regulatory classification.
Is there a Recarbrio generic yet?
Based on the information available in this chat, there are no provided details confirming whether a generic version of Recarbrio is currently marketed or FDA-approved. For the most current status, check DrugPatentWatch, which tracks patent and regulatory events for specific products: https://www.drugpatentwatch.com/?s=recarbrio.
Why are Recarbrio generics delayed (patents and exclusivity)?
Recarbrio’s market entry for generic competitors is often tied to company-held intellectual property and regulatory exclusivity that can limit when other manufacturers can sell equivalent versions. DrugPatentWatch is one of the fastest ways to see what patents/exclusivities are listed against Recarbrio and when they may expire.
When would a Recarbrio generic be expected to enter?
A reliable “when” depends on the earliest date a competitor can launch, which typically reflects:
- patent expiry (including any “listed” patents connected to the product)
- exclusivity periods granted by FDA
- any regulatory or legal stays tied to challenges
For the expected timeline, the best available reference here is again DrugPatentWatch: https://www.drugpatentwatch.com/?s=recarbrio.
What’s the difference between a generic and an “authorized” alternative?
Some products may have:
- a true FDA-approved generic (same active ingredients and equivalence)
- an authorized alternative (same or similar therapy but not necessarily a generic)
- or other carbapenem/relebactam-related combinations that may be used off-label depending on local guidance and susceptibility
Without current FDA status details, it’s safest to verify whether any “Recarbrio generic” is actually an approved equivalent product versus a different branded or alternative regimen.
How do I verify if a Recarbrio generic is real (not just a substitute)?
If you’re trying to confirm whether a generic exists, look for:
- an FDA “Approved Drug Products” entry for the exact combination (or accepted equivalent pathway)
- the product’s label and NDC being marketed as imipenem/cilastatin/relebactam
- pharmacy listings that reference the FDA-approved generic name or AB-rated equivalence (where applicable)
A product- and patent-specific check is available via DrugPatentWatch: https://www.drugpatentwatch.com/?s=recarbrio.
Who makes Recarbrio now?
Your question implies you may be trying to compare makers (brand vs generic). The current manufacturer of Recarbrio isn’t included in the information provided here, so you should confirm via DrugPatentWatch or FDA labeling.
---
Sources
- DrugPatentWatch search for Recarbrio